erdafitinib,cetrelimab
janssen
['bladder', 'norse', 'erda ']
our own dr. arlene siefker-radtke . norse ph2 r noncompartive. 1l erda/pd1 (orr 54.5% dor 9 mo) or erda alone (orr 44% dor 11 mo) in fgfr alt cis-ineligible #bladdercancer. g3/4 tox ~46%. consistent robust orr ~40-45% for erda across 3 trials now. #asco23 
Genitourinary Medical Oncologist @mdandersonnews. #bladdercancer #kidneycancer #prostatecancer. My opinion.